RITUXIMAB VERSUS SPLENECTOMY IN CHRONIC PRIMARY ITP: EXPERIENCE OF A SINGLE HEMATOLOGY CLINIC
Main Article Content
Keywords
ITP, rituximab, splenectomy, complete response, second-line therapy
Abstract
Objective: Immune thrombocytopenia (ITP) is an acquired immune-mediated disease that lacks an underlying etiology. Steroids are the main first-line treatment of ITP, while the second-line treatment consists primarily of splenectomy and rituximab. This study aimed to assess and compare the response to rituximab and splenectomy.
Methods: This retrospective comparative study reviewed ITP patients treated at a single private hematology clinic from 2007 to 2019. Seventy-four ITP patients were recruited, 27 were on rituximab, and 47 had undergone splenectomy. The initial platelet counts and bleeding symptoms were recorded, and initial and long-term responses to treatment were evaluated based on the American Society of Hematology guidelines.
Results: The mean age of the patients was 42.1 years with a male-to-female ratio of 1:1.8. The initial mean platelet count was comparable between the rituximab and splenectomy groups (p = 0.749). The initial complete response (CR) differed significantly between the rituximab and splenectomy groups (44.4% versus 83%, p = 0.002). The five-year response rate was significantly higher in the splenectomy than in the rituximab group (74% versus 52%, log-rank 0.038). Splenectomy was the only significant predictive factor for long-term response (OR = 0.193, p = 0.006).
Conclusion: The overall response revealed that splenectomy appeared superior to rituximab as a second-line treatment of ITP. Splenectomy was the only positive prognostic indicator of sustained response.
Downloads
Abstract 237
PDF Downloads 179
HTML Downloads 12
References
2. Al Askar AS, Shaheen NA, Al Zahrani M, et al. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience. Int J Hematol. 2018;107:69–74. doi:10.1007/s12185-017-2325-y
3. Stasi R, Newland A, Thornton P, Pabinger I. Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. Ann Hematol. 2010;89:1185–1195. doi:10.1007/s00277-010-1066-2
4. Cooper N, Ghanima W. Immune Thrombocytopenia. N Engl J Med. 2019; 381:945–955. doi:10.1056/NEJMcp1810479
5. Abrahamson PE, Hall SA, Feudjo-Tepie M, et al. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol. 2009;83:83–89. doi:10.1111/j.1600-0609.2009.01247.x
6. Feng R, Zhang HX, Chen CY. Rituximab should be used earlier in ITP patients: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 2016;9:918-926.
7. Auger S, Duny Y, Rossi JF, et al. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol. 2012;158:386–398. doi:10.1111/j.1365-2141.2012.09169.x
8. Bussel JB, Lee CS, Seery C, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 2014;99:1264–1271. doi:10.3324/haematol.2013.103291
9. Lucchini E, Zaja F, Bussel J. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica. 2019;104:1124–1135. doi:10.3324/haematol.2019.218883
10. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–2393. doi:10.1182/blood-2008-07-162503
11. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190–4207. doi:10.1182/blood-2010-08-302984
12. Palandri F, Polverelli N, Sollazzo D, et al. Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. Am J Hematol. 2016;91:E267-272. doi:10.1002/ajh.24310
13. Zaja F, Volpetti S, Chiozzotto M, et al. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol. 2012;87:886–889. doi: 10.1002/ajh.23272
14. Ahmed R, Devasia AJ, Viswabandya A, et al. Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children : Splenectomy in ITP. Ann Hematol. 2016;95:1429–34. doi:10.1007/s00277-016-2738-3
15. Andrès E. What impact for sex difference on immune thrombocytopenic purpura? Women Health Open J. 2016;2:e1–3. doi: 10.17140/WHOJ-2-e004
16. Provan D, Newland AC. Current management of primary immune thrombocytopenia. Adv Ther. 2015;32:875–887. doi: 10.1007/s12325-015-0251-z
17. Moulis G, Sailler L, Sommet A, et al. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity. Am J Hematol. 2014;89:41–46. doi:10.1002/ajh.23580
18. Brah S, Chiche L, Fanciullino R, et al. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey. Ann Hematol. 2012;91:279–285. doi: 10.1007/s00277-011-1283-3
19. Dabak V, Hanbali A, Kuriakose P. Can rituximab replace splenectomy in immune thrombocytopenic purpura? Indian J Hematol Blood Transfus. 2009;25:6–9. doi: 10.1007/s12288-009-0002-x
20. Chater C, Terriou L, Duhamel A, et al. Reemergence of Splenectomy for ITP Second-line Treatment? Ann Surg. 2016;264:772–777. doi: 10.1097/SLA.0000000000001912
21. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119:5989–5995. doi: 10.1182/blood-2011-11-393975
22. Choi PYI, Roncolato F, Badoux X, et al. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015;126:500–503. doi: 10.1182/blood-2015-03-631937
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.